Schmidt-Kraepelin, Christian
Feyerabend, Sandra
Engelke, Christina
Riesbeck, Mathias
Meisenzahl-Lechner, Eva
Gaebel, Wolfgang
Verde, Pablo-Emilio
Kolbe, Henrike
Correll, Christoph U.
Leucht, Stefan
Heres, Stephan
Kluge, Michael
Makiol, Christian
Neff, Andrea
Lange, Christina
Englisch, Susanne
Zink, Mathias
Langguth, Berthold
Poeppl, Timm
Reske, Dirk
Gouzoulis-Mayfrank, Euphrosyne
Gründer, Gerhard
Hasan, Alkomiet
Brockhaus-Dumke, Anke
Jäger, Markus
Baumgärtner, Jessica
Wobrock, Thomas
Cordes, Joachim
Funding for this research was provided by:
German Federal Ministry of Education and Research (BMBF 01KG1102)
Article History
Received: 7 March 2019
Accepted: 23 August 2019
First Online: 5 September 2019
Compliance with ethical standards
:
: C Schmidt-Kraepelin, S. Feyerabend, C. Engelke, M. Riesbeck, E. Meisenzahl-Lechner, P. E. Verde, S. Heres, H. Kolbe, C. Makiol, A. Neff, C. Lange, T. Poeppl, D. Reske, E. Gouzoulis-Mayfrank, A. Brockhaus-Dumke, M. Jäger, J. Baumgärtner have no conflicts of interests to declare. W. Gaebel is a member of the Faculty of the Lundbeck International Neuroscience Foundation, Denmark. C. U. Correll has been a consultant and/or advisor to or has received honoraria from: Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, Rovi, Servier, Sunovion, Supernus, Takeda, and Teva. He has provided expert testimony for Bristol-Myers Squibb, Janssen, and Otsuka. He served on a Data Safety Monitoring Board for Boehringer-Ingelheim, Lundbeck, Rovi, Supernus, and Teva. He received royalties from UpToDate and grant support from Janssen and Takeda. He is also a shareholder of LB Pharma. S. Leucht has received honoraria for consulting or lectures from LB Pharma, Lundbeck, Otsuka, TEVA, LTS Lohmann, Geodon Richter, Recordati, Boehringer Ingelheim, Sandoz, Janssen, Lilly, SanofiAventis, Servier and Sunovion in the last 3 years. M. Kluge has received honoraria from Roche, Servier, and Tromssdorff. S. Englisch received travel expenses and consultant fees from Janssen-Cilag, Lundbeck, Otsuka Pharma, and Servier. M. Zink received scientific grants from the German Research Foundation, and Servier; speaker and travel grants were provided from Otsuka, Servier, Lundbeck, Roche, Ferrer, and Trommsdorff. B. Langguth received honoraria and speakers’ fees from ANM, AstraZeneca, Autifony Therapeutics, Desyncra, Lundbeck, Merz, MagVenture, Neurolite, Neuromod, Novartis, Pfizer, and Servier; research funding from the Tinnitus Research Initiative, the German Research Foundation, the German Bundesministerium für Bildung und Forschung, the American Tinnitus Association, AstraZeneca, and cerbomed; funding for equipment from MagVenture and Deymed Diagnostic; and travel and accommodation payments from Eli Lilly, Lundbeck, Servier, and Pfizer. G. Gründer has served as a consultant for Allergan (Dublin, Ireland), Boehringer Ingelheim (Ingelheim, Germany), Eli Lilly (Indianapolis, Ind, USA), Janssen-Cilag (Neuss, Germany), Lundbeck (Copenhagen, Denmark), Ono Pharmaceuticals (Osaka, Japan), Otsuka (Chiyoda, Japan), Recordati (Milan, Italy), Roche (Basel, Switzerland), Servier (Paris, France), and Takeda (Osaka, Japan). He has served on the speakers’ bureau of Eli Lilly, Janssen Cilag, Neuraxpharm (Langenfeld, Germany), Lundbeck, Otsuka, Recordati, Roche, Servier, and Trommsdorf (Aachen, Germany). He has received grant support from Boehringer Ingelheim and Roche. He is co-founder of Mind and Brain Institute GmbH (Zornheim, Germany) and Brainfoods GmbH (Zornheim, Germany). A. Hasan has been in the advisory board of Janssen-Cilag, Lunbeck, Roche and Otsuka and has accepted paid speaking engagements for Janssen-Cilag, Lunbeck and Otsuka. T. Wobrock was a member of the Advisory Board of Janssen Cilag and Otsuka/Lundbeck and has accepted paid speaking engagements for Alpine Biomed, AstraZeneca, Bristol Myers Squibb, Eli Lilly, I3G, Glaxo-Smith-Kline, Janssen Cilag, Novartis, Lundbeck, Otsuka, Roche, Sanofi-Aventis and Pfizer. He has received a research grant from AstraZeneca, Cerbomed, I3G and AOK (health insurance company). In addition he received research support from The German Research Funding Organisation (DFG) and the Federal Ministry of Education and Research (BMBF). J. Cordes was a member of an advisory board of Roche, accepted travel or hospitality not related to a speaking engagement from Servier, support for symposia from Inomed, Localite, Magventure, Roche, Mag and More, NeuroConn, Syneika, FBI Medizintechnik, Spitzer Arzneimittel and Diamedic, research and study participation funded by the German Research Foundation and the German Bundesministerium für Bildung und Forschung, Foundation European Group for Research In Schizophrenia, ACADIA Pharmaceuticals Inc., Boehringer Ingelheim Pharma GmbH and Co. KG, Otsuka Pharmaceutical Europe Ltd. and EnVivo Pharmaceuticals.